Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793942 | 1.00 | POLB (0.52) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL6800845 | 1.00 | POLB (0.52) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL6207334 | 0.89 | POLB (0.44) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL5369171 | 0.88 | POLB (0.60) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL8542907 | 0.88 | POLB (0.60) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL6079619 | 0.85 | POLB (0.50) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL6994848 | 0.84 | POLB (0.49) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL28559612 | 0.82 | POLB (0.46) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL28244523 | 0.81 | POLB (0.45) | POLBNPC1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL15671079 | 0.81 | ABCB1 (0.48) | POLBNPC1ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740651-B2 | TREATING PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-25 | — | — | US | disclosed |
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K20, MAP3K19 | POLB 3555/4885NPC1 4390/4885ALDH1A1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.